Consistent with these results suggesting that MYC mRNA levels are modulated by constitutively activated FGFR3, an analysis of previously described transcriptomic data for our CIT‐series (“Carte d'Identité des Tumeurs”; tumor identity card) of bladder tumors revealed a significant upregulation of MYC mRNA levels in tumors harboring an FGFR3 mutation (n = 63) relative to normal urothelium samples (n = 4), whereas no such overexpression was observed for tumors expressing wild‐type FGFR3 (n = 122; Fig 1C). This evidence concerns the gene FGFR3 and neoplasm.